Scopus BioPharma Inc. (SCPS): BCG Matrix [Dec-2025 Updated]

You're looking for a clear-eyed view of Scopus BioPharma Inc.'s (SCPS) portfolio as of late 2025, and the reality is simple: this isn't a company with established revenue streams; it's a pure-play development story. We find zero Stars or Cash Cows, leaving the entire enterprise categorized as a high-stakes 'Question Mark' centered entirely around the T-VEC-CD40L candidate, while the 'Dogs' quadrant highlights the unavoidable G&A overhead funding this critical, pre-revenue phase. Dive in below to see the precise breakdown of this single-asset risk profile.

Background of Scopus BioPharma Inc. (SCPS)

You're looking at Scopus BioPharma Inc. (SCPS), a company that started back in 2017. Honestly, when you review their profile, you see a firm that has been focused on developing novel therapeutics for diseases where current treatments just aren't cutting it. The company's core mission has centered on developing treatments that target the endocannabinoid system, though their pipeline also shows a strong push into immuno-oncology gene therapy for various cancers. They conduct their research and early development activities in the United States, with a corporate office listed in New York, NY, though another source points to Newtown, Pennsylvania.

The product pipeline is what really defines Scopus BioPharma Inc. right now. You'll see their lead programs involve small-molecule compounds aimed at giving relief to patients dealing with chronic neuropathic pain and episodic migraine. A key technology platform mentioned is the Duet Platform, which includes CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Specifically, their product candidates include CO-sTiRNA, which is a STAT3 inhibitor gene therapy, and MRI-1867. It's worth noting that recent news in November 2025 suggested an FDA green light for a CpG-STAT3siRNA trial, which is a significant near-term event for any clinical-stage biotech.

From a market perspective as of late 2025, the picture is quite stark. As of December 4, 2025, the stock price for Scopus BioPharma Inc. was trading at approximately $0.0005 per share. You should definitely note that one source indicates the company has been delisted, which is a critical piece of context for any investment analysis. For context on recent volatility, the 52-week high was reported at $0.0100, while the 52-week low dipped to $0.0002. The last reported trailing 12-month revenue, based on mid-2023 data, was null, which isn't surprising for a company deep in the clinical stages, but it shows you where the value is purely speculative, resting on pipeline success.

Scopus BioPharma Inc. (SCPS) - BCG Matrix: Stars

You're looking at the Stars quadrant, which is reserved for products that have a commanding lead in a market that's expanding rapidly. For Scopus BioPharma Inc., the reality right now is that this quadrant remains empty.

The fundamental requirement for a Star-high market share in a growing market-is not met by any current offering from Scopus BioPharma Inc. The Trailing Twelve Month (TTM) revenue, based on the latest available filings, stands at $0.00 USD, which immediately disqualifies any product from being a revenue-generating leader.

Your lead asset, T-VEC-CD40L, is firmly in the research and development pipeline. Because it has not achieved commercial launch, it is, by definition, pre-revenue. This status means it cannot contribute to the high cash generation required to be classified as a Star, even if the underlying market growth potential is significant.

The company's current operational profile reflects a pure-play biotechnology firm focused on early-to-mid-stage development. The focus is entirely on advancing the pipeline, not defending market share in a commercial segment. As of the last reported figures, the market capitalization sits around $2.07M USD, which reflects a valuation based on future potential rather than current product dominance.

Here's a quick look at the financial context that supports the absence of Stars:

The pipeline composition clearly shows where the investment dollars are going, which is necessary for future growth but not for current market leadership:

• Focus on developing therapeutics targeting the endocannabinoid system.
• Product candidates include CO-sTiRNA and MRI-1867.
• The company's strategy is centered on IND submissions and clinical trial progression.
• No current product has achieved market penetration or sales volume.

Scopus BioPharma Inc. (SCPS) - BCG Matrix: Cash Cows

Cash cows are market leaders generating more cash than they consume. For Scopus BioPharma Inc. (SCPS), the current financial profile does not align with the characteristics of a Cash Cow business unit.

The following data points reflect the absence of the required characteristics for a Cash Cow designation for Scopus BioPharma Inc. (SCPS) based on the latest available figures:

• Zero approved drugs or revenue-generating intellectual property (IP) assets.
• No established product line to provide stable, low-growth cash flow.
• The company operates with a negative cash flow, not a positive cash surplus.
• Relies on equity financing, not product sales, for capital.

The financial reality shows a reliance on past capital raises rather than product sales to sustain operations.

The company's product development pipeline includes candidates like CO-sTiRNA, a STAT3 inhibitor gene therapy, and MRI-1867, focusing on autoimmune, inflammatory, metabolic diseases, and cancer. These are early-stage assets, not revenue-generating products.

The financial structure indicates a pre-revenue stage, which is inconsistent with a Cash Cow profile. The reliance on external capital is evidenced by the total funding raised.

• Total Funding Raised: $9.34M.
• Latest Major Round: Series B of $6.35M in Jul 2020.
• Net Income (Recent Period 1): -$11.7M.
• Net Income (Recent Period 2): -$27.0M.
• Stock Price (as of 11-Aug-2023): $0.05.
• Market Capitalization (as of 11-Aug-2023): $2.07M.

To maintain productivity, Scopus BioPharma Inc. (SCPS) would need to secure further financing, as product sales do not currently generate the required cash flow.

Scopus BioPharma Inc. (SCPS) - BCG Matrix: Dogs

You're looking at the parts of Scopus BioPharma Inc. (SCPS) that aren't generating significant cash flow or showing high market growth right now. These are the units that tie up capital without a clear, near-term return.

Corporate general and administrative (G&A) overhead without corresponding revenue.

The financial structure suggests cash consumption rather than generation in the absence of product sales. As of 30-Jun-2023, the trailing 12-month revenue was $\text{null}$. The Earnings Per Share (EPS) for the 12 months ending 11-Aug-2023 was $\mathbf{-\$0.31}$. For context, the FY 2022 revenue was $\mathbf{1,746}$ (in thousands USD). The Price-to-Earnings ratio (P/E TTM) is reported as $\mathbf{0.00}$.

Early-stage, non-core research programs that have not advanced significantly.

The portfolio structure includes assets that, by definition in this matrix, are not yet generating revenue. The company's pipeline lists specific drug candidates, but other programs fall into this category:

• Drug Candidate: $\text{CO-sTiRNA}{\text{TM}}$
• Drug Candidate: $\text{MRI-1867}$
• Existence of $\mathbf{\text{Additional R\&D Programs}}$

The SCPS ticker status itself, reflecting low trading volume and market interest.

The market activity reflects minimal investor interest, a classic sign of a Dog or a Question Mark that hasn't yet captured market attention. Here are the trading metrics as of December 4, 2025:

Legacy IP or patents not directly related to the T-VEC-CD40L platform.

While the focus is on the T-VEC-CD40L platform, any older or peripheral intellectual property that requires maintenance costs without a clear path to monetization contributes to the Dog classification. Specific financial carrying costs for this legacy IP are not publicly itemized, but the overall low market cap of $\mathbf{\$21.04K}$ suggests minimal capital is currently allocated to non-core assets.

Expensive turn-around plans are generally ill-advised here; the strategy should lean toward minimizing cash drain.

Scopus BioPharma Inc. (SCPS) - BCG Matrix: Question Marks

The lead oncology candidate, T-VEC-CD40L, targets the cancer immunotherapy market, which is characterized by substantial growth prospects. The global cancer immunotherapy market size was valued at USD 226.38 billion in 2024 and is projected to reach USD 443.17 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 11.90% from 2025 to 2030. The U.S. segment of this market was estimated at USD 36.54 billion in 2024 and is predicted to be worth around USD 106.35 billion by 2034, growing at a CAGR of 11.27% from 2025 to 2034.

The development path for T-VEC-CD40L necessitates high investment for Phase 1/2 clinical trials. This stage carries inherently uncertain success rates; for context, the success rate for Phase 1 drugs plummeted to just 6.7% in 2024 across the industry.

As a pre-commercial asset, Scopus BioPharma Inc. (SCPS) currently holds zero market share for T-VEC-CD40L. However, the potential is significant, with the goal being to capture a share of the market that is projected to grow substantially, as seen in the CD40/CD40L inhibitors segment which is expected to surge significantly by 2034.

The required clinical development translates directly into significant R&D expenses, defintely leading to a high cash burn rate for Scopus BioPharma Inc. (SCPS). For comparison, some emerging biopharma companies project annual cash burn rates that can approach or exceed $450 million for the full year 2025, excluding financing inflows.

The entire corporate entity, Scopus BioPharma Inc. (SCPS), is positioned as a Question Mark given its single-asset, high-risk development stage, consuming cash to advance the asset toward potential market entry. The company must rapidly increase market share potential through clinical success or face becoming a Dog. The best way to handle Question Marks is to either invest heavily to gain market share or to sell them.

The high-growth market context for Scopus BioPharma Inc. (SCPS) is summarized below:

The strategic focus for Scopus BioPharma Inc. (SCPS) revolves around these key development milestones:

• Achieve successful progression through Phase 1/2 clinical trials.
• Secure subsequent, substantial investment rounds or partnerships.
• Rapidly convert high R&D expenditure into positive clinical data.
• Establish a clear path to achieving multi-billion dollar peak sales potential.